Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.72 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | F2R | P25116 | 9/20 | 0.68 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23070709 | 0.89 | KMT2A (0.68) | KMT2AMEN1SMN1; SMN2F2RNPC1 | |
| SCHEMBL3663484 | 0.85 | KMT2A (0.61) | KMT2AMEN1F2RNPC1RAB9A | |
| SCHEMBL882734 | 0.85 | KMT2A (0.80) | KMT2AMEN1TP53SMN1; SMN2F2R | |
| SCHEMBL2298254 | 0.85 | KCNK3 (1.00) | KMT2AMEN1KCNK3KCNK9TP53 | |
| SCHEMBL10069454 | 0.84 | F2R (0.72) | KMT2ASMN1; SMN2F2RNPC1RAB9A | |
| SCHEMBL22362618 | 0.83 | KCNK3 (0.71) | KMT2AMEN1KCNK3KCNK9F2R | |
| SCHEMBL22362609 | 0.83 | F2R (0.63) | KMT2AMEN1F2RNPC1RAB9A | |
| SCHEMBL16270629 | 0.82 | KMT2A (0.58) | KMT2AMEN1F2RNPC1RAB9A | |
| SCHEMBL10069459 | 0.82 | KMT2A (0.66) | KMT2AMEN1KCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL12310041 | 0.82 | KMT2A (1.00) | KMT2AMEN1KCNK3KCNK9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |